Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

autoimmune disease

Sanofi reception

Sanofi’s PD-1 inhibitor starts EU review for skin cancer

Cemiplimab could be the first PD-1-targeting drug approved for CSCC

Sanofi reception

Sanofi, Regeneron offer price cut for cholesterol drug Praluent

Amgen’s Repatha also struggled to secure reimbursement at its launch price point

Sanofi reception

Sanofi taps Evotec for new anti-infectives drive

The duo will set up the initiative at Sanofi’s R&D unit in France

BenevolentAI claims AI first with new Cambridge facility

Says its new drug discovery and development base will cover the entire research process

- PMLiVE

Diagnostics firm Diaceutics signs AI collaboration with Lenovo and Intel

Will use artificial intelligence to improve cancer outcomes

Sanofi ponders which African health tech start-ups to bring to Paris

It's on the look out for those working in non-communicable diseases, telemedicine and HCP education

Microsoft brings its AI network to cardiology

Also launches cloud-based genomics service for its Azure platform

FDA approves AI-based decision support software

Viz.AI Contact alerts healthcare professionals if a patient is at risk of stroke

- PMLiVE

Smart watch epilepsy monitor cleared by FDA

Approval could potentially clear the way for insurers to reimburse its cost

Sanofi reception

Ablynx spurns Novo Nordisk and cuts €3.9bn deal with Sanofi

The offer comes at a 110% premium on the Belgian biopharma’s share price

- PMLiVE

Dominique Carouge joins Sanofi as head of business transformation

He also becomes a member of the executive committee

Sanofi reception

Third time lucky? Sanofi cuts an $11.6bn deal to buy Bioverativ

French pharma firm offers $105 apiece for the spin-out’s shares

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links